By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is ...

Stocks mostly edged downwards on Monday, after rallies in Europe and the US fueled by comments from the US central bank chief last week where he indicated the possibility of lower interest rates.

EUROPEAN shares closed lower on Monday, giving back Friday’s gains on optimism around US monetary policy easing, while JDE ...

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

There have been 4 new reports of serious adverse events related to Ixchiq based on updated Vaccine Adverse Event Reporting System data.

European shares closed lower on Monday, giving back Friday's gains on optimism around U.S. monetary policy easing, while JDE ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

The FDA suspended the license for vaccine manufacturer Valneva’s chikungunya vaccine following reports of serious adverse events. The decision halts all shipping and sales of the vaccine in the U.S., ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

Hey, good morning. Today, we see CBER suspend the license for a chikungunya vaccine, look at a push to recall a safety and ...